{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:22:01Z","timestamp":1776316921161,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11926-018-0722-8","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T03:35:19Z","timestamp":1520480119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Are Doctors the Best People to Manage Gout? Is There a Role for Nurses and Pharmacists?"],"prefix":"10.1007","volume":"20","author":[{"given":"Zahira","family":"Latif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"issue":"4","key":"722_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"C-F Kuo","year":"2014","unstructured":"\u2022 Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014;74(4):661\u20137. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2013-204463\n                      \n                    . Epidemiology of gout is described in this study","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"722_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/acr.21791","volume":"65","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Miller ER 3rd, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988\u20131994 and 2007\u20132010. Arthritis Care & Research. 2013;65(1):127\u201332. \n                      https:\/\/doi.org\/10.1002\/acr.21791\n                      \n                    .","journal-title":"Arthritis Care & Research."},{"issue":"9711","key":"722_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T. Gout. Lancet (London, England). 2010;375(9711):318\u201328. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(09)60883-7\n                      \n                    .","journal-title":"Lancet (London, England)"},{"issue":"6","key":"722_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/art.39581","volume":"68","author":"M Andres","year":"2016","unstructured":"Andres M, Quintanilla MA, Sivera F, Sanchez-Paya J, Pascual E, Vela P, et al. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthr Rheumatol= (Hoboken, NJ). 2016;68(6):1531\u20139. \n                      https:\/\/doi.org\/10.1002\/art.39581\n                      \n                    .","journal-title":"Arthr Rheumatol= (Hoboken, NJ)"},{"issue":"1","key":"722_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2011.154997","volume":"71","author":"E Miguel De","year":"2012","unstructured":"De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71(1):157\u20138. \n                      https:\/\/doi.org\/10.1136\/ard.2011.154997.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"722_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7861\/clinmedicine.17-1-54","volume":"17","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Roddy E, Doherty M. Gout\u2014a guide for the general and acute physicians. Clin Med (Lond). 2017;17(1):54\u20139. \n                      https:\/\/doi.org\/10.7861\/clinmedicine.17-1-54\n                      \n                    .","journal-title":"Clin Med (Lond)"},{"issue":"10","key":"722_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/acr.22855","volume":"68","author":"A Abhishek","year":"2016","unstructured":"\u2022 Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: a case-control study. Arthritis care & research. 2016;68(10):1573\u20137. \n                      https:\/\/doi.org\/10.1002\/acr.22855\n                      \n                    . Longer disease duration and higher serum urate assiciates with gout floves","journal-title":"Arthritis care & research"},{"issue":"11","key":"722_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/ard.2008.096693","volume":"68","author":"AJ Elliot","year":"2009","unstructured":"Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994\u20132007. Ann Rheum Dis. 2009;68(11):1728\u201333. \n                      https:\/\/doi.org\/10.1136\/ard.2008.096693.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"722_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/rheumatology\/kes253","volume":"52","author":"PC Robinson","year":"2013","unstructured":"Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999\u20132009. Rheumatol (Oxford, England). 2013;52(1):118\u201326. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kes253.","journal-title":"Rheumatol (Oxford, England)"},{"key":"722_CR10","unstructured":"Parsons S, Ingram, M., Clarke-Cornwell, M. A., Symmons, D. P. A heavy burden. In: A heavy burden. The University of Manchester, Manchester. 2011. Accessed 23\/05\/2017 2017."},{"issue":"4","key":"722_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/rheumatology\/kew395","volume":"56","author":"A Abhishek","year":"2017","unstructured":"\u2022\u2022 Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatol (Oxford, England). 2017;56(4):529\u201333. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kew395\n                      \n                    . Demonstrates long-term adherence and persistence of urate lowering treatment","journal-title":"Rheumatol (Oxford, England)"},{"issue":"6","key":"722_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826\u201330. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2012-201676\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"722_CR13","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1001\/jama.2014.14484","volume":"312","author":"CF Kuo","year":"2014","unstructured":"\u2022 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684\u20136. \n                      https:\/\/doi.org\/10.1001\/jama.2014.14484\n                      \n                    . Demonstrates poor urate lowering prescription rates in UK gout patients","journal-title":"JAMA"},{"issue":"4","key":"722_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"\u2022\u2022 Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632\u20138. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-209467\n                      \n                    . Treat to target recommendation for gout","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"722_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatol (Oxford, England). 2007;46(8):1372\u20134. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kem056a\n                      \n                    .","journal-title":"Rheumatol (Oxford, England)."},{"issue":"8","key":"722_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2215\/CJN.11451210","volume":"6","author":"M Kanbay","year":"2011","unstructured":"Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol : CJASN. 2011;6(8):1887\u201394. \n                      https:\/\/doi.org\/10.2215\/cjn.11451210\n                      \n                    .","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"issue":"9","key":"722_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3899\/jrheum.141542","volume":"42","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694\u2013701. \n                      https:\/\/doi.org\/10.3899\/jrheum.141542\n                      \n                    .","journal-title":"J Rheumatol"},{"issue":"12","key":"722_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145193","volume":"10","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One. 2015;10(12):e0145193. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0145193\n                      \n                    .","journal-title":"PLoS One"},{"issue":"5","key":"722_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3346\/jkms.2014.29.5.657","volume":"29","author":"K Joo","year":"2014","unstructured":"Joo K, Kwon SR, Lim MJ, Jung KH, Joo H, Park W. Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. J Korean Med Sci. 2014;29(5):657\u201361. \n                      https:\/\/doi.org\/10.3346\/jkms.2014.29.5.657\n                      \n                    .","journal-title":"J Korean Med Sci"},{"issue":"3","key":"722_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.amjmed.2015.11.003","volume":"129","author":"KS Larsen","year":"2016","unstructured":"Larsen KS, Pottegard A, Lindegaard HM, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129(3):299\u2013306 e2. \n                      https:\/\/doi.org\/10.1016\/j.amjmed.2015.11.003\n                      \n                    .","journal-title":"Am J Med"},{"issue":"6","key":"722_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1755-5922.12215","volume":"34","author":"W Xin","year":"2016","unstructured":"Xin W, Mi S, Lin Z. Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials. Cardiovasc Ther. 2016;34(6):441\u20139. \n                      https:\/\/doi.org\/10.1111\/1755-5922.12215\n                      \n                    .","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"722_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10157-012-0742-z","volume":"17","author":"H Terawaki","year":"2013","unstructured":"Terawaki H, Nakayama M, Miyazawa E, Murata Y, Nakayama K, Matsushima M, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clin Exp Nephrol. 2013;17(4):549\u201353. \n                      https:\/\/doi.org\/10.1007\/s10157-012-0742-z\n                      \n                    .","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"722_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","volume":"17","author":"JA Singh","year":"2017","unstructured":"Singh JA, Ramachandaran R, Yu S, Curtis JR. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord. 2017;17(1):76. \n                      https:\/\/doi.org\/10.1186\/s12872-017-0513-6.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"722_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16(1):58. \n                      https:\/\/doi.org\/10.1186\/s12882-015-0047-z\n                      \n                    .","journal-title":"BMC Nephrol"},{"issue":"2","key":"722_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dialysis Trans : Off Publ Eur Dialysis Trans Assoc-Eur Renal Assoc. 2014;29(2):406\u201313. \n                      https:\/\/doi.org\/10.1093\/ndt\/gft378\n                      \n                    .","journal-title":"Nephrol Dialysis Trans : Off Publ Eur Dialysis Trans Assoc-Eur Renal Assoc"},{"issue":"9","key":"722_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","volume":"71","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71(9):1490\u20135. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2011-200801.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"722_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s10067-015-3039-2","volume":"35","author":"P Chandratre","year":"2016","unstructured":"\u2022 Chandratre P, Mallen CD, Roddy E, Liddle J, Richardson J. \u201cYou want to get on with the rest of your life\u201d: a qualitative study of health-related quality of life in gout. Clin Rheumatol. 2016;35(5):1197\u2013205. \n                      https:\/\/doi.org\/10.1007\/s10067-015-3039-2\n                      \n                    . Qualitative study of impact of gout on patients","journal-title":"Clin Rheumatol"},{"issue":"3","key":"722_CR28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1071\/HC13214","volume":"5","author":"L Karu Te","year":"2013","unstructured":"Te Karu L, Bryant L, Elley CR. Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study. J Prim Health Care. 2013;5(3):214\u201322.","journal-title":"J Prim Health Care"},{"issue":"11","key":"722_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/acr.22879","volume":"68","author":"SD Duyck","year":"2016","unstructured":"\u2022 Duyck SD, Petrie KJ, Dalbeth N. \u201cYou don\u2019t have to be a drinker to get gout, but it helps\u201d: a content analysis of the depiction of gout in popular newspapers. Arthritis Care & Research. 2016;68(11):1721\u20135. \n                      https:\/\/doi.org\/10.1002\/acr.22879\n                      \n                    . Qualitative study of impact of gout on patients","journal-title":"Arthritis Care & Research."},{"issue":"1","key":"722_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3899\/jrheum.150607","volume":"43","author":"S Vaccher","year":"2016","unstructured":"\u2022 Vaccher S, Kannangara DR, Baysari MT, Reath J, Zwar N, Williams KM, et al. Barriers to care in gout: from prescriber to patient. J Rheumatol. 2016;43(1):144\u20139. \n                      https:\/\/doi.org\/10.3899\/jrheum.150607\n                      \n                    . Qualitative study of gout patients and their doctors","journal-title":"J Rheumatol"},{"issue":"suppl_1","key":"722_CR31","doi-asserted-by":"publisher","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","volume":"57","author":"A Abhishek","year":"2018","unstructured":"\u2022\u2022 Abhishek A, Doherty M. Education and non-pharmacological approaches for gout. Rheumatology. 2018;57(suppl_1):i51\u2013i8. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kex421\n                      \n                    . Describes current state of mis-information about gout","journal-title":"Rheumatology"},{"issue":"5","key":"722_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908\u201311. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2014-206397\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"722_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10067-014-2644-9","volume":"34","author":"JD Carter","year":"2015","unstructured":"Carter JD, Patelli M, Anderson SR, Prakash N, Rodriquez EJ, Bateman H, et al. An MRI assessment of chronic synovial-based inflammation in gout and its correlation with serum urate levels. Clin Rheumatol. 2015;34(2):345\u201351. \n                      https:\/\/doi.org\/10.1007\/s10067-014-2644-9\n                      \n                    .","journal-title":"Clin Rheumatol"},{"issue":"4","key":"722_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/1754-9485.12306","volume":"59","author":"I Popovich","year":"2015","unstructured":"Popovich I, Lee AC, Doyle A, McHaffie A, Clarke A, Reeves Q, et al. A comparative MRI study of cartilage damage in gout versus rheumatoid arthritis. J Med Imagin Radiat Oncol. 2015;59(4):431\u20135. \n                      https:\/\/doi.org\/10.1111\/1754-9485.12306\n                      \n                    .","journal-title":"J Med Imagin Radiat Oncol"},{"issue":"7","key":"722_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","volume":"76","author":"MC Fisher","year":"2017","unstructured":"Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76(7):1289\u201394. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210588\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"722_CR36","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1002\/art.39813","volume":"68","author":"SP Juraschek","year":"2016","unstructured":"Juraschek SP, Gelber AC, Choi HK, Appel LJ, Miller ER 3rd. Effects of the dietary approaches to stop hypertension (DASH) diet and sodium intake on serum uric acid. Arthritis & Rheumatology (Hoboken, NJ). 2016;68(12):3002\u20139. \n                      https:\/\/doi.org\/10.1002\/art.39813\n                      \n                    .","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"722_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1475-2891-11-39","volume":"11","author":"A Kanbara","year":"2012","unstructured":"Kanbara A, Miura Y, Hyogo H, Chayama K, Seyama I. Effect of urine pH changed by dietary intervention on uric acid clearance mechanism of pH-dependent excretion of urinary uric acid. Nutr J. 2012;11:39. \n                      https:\/\/doi.org\/10.1186\/1475-2891-11-39\n                      \n                    .","journal-title":"Nutr J"},{"issue":"1","key":"722_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2016","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016;76(1):29\u201342. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"722_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA Vera De","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis care & Res. 2014;66(10):1551\u20139. \n                      https:\/\/doi.org\/10.1002\/acr.22336\n                      \n                    .","journal-title":"Arthritis care & Res"},{"issue":"4","key":"722_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437\u201343. \n                      https:\/\/doi.org\/10.1592\/phco.28.4.437\n                      \n                    .","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"722_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/annrheumdis-2017-eular.5006","volume":"76","author":"M Doherty","year":"2017","unstructured":"\u2022\u2022 Doherty M, Jenkins W, Richardson H, Abhishek A, Ashton D, Barclay C, et al. OP0268 nurse-led care versus general practitioner care of people with gout: a UK community-based randomised controlled trial. Ann Rheum Dis. 2017;76(Suppl 2):167. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.5006\n                      \n                    . 2 year RCT of nurse led versus usual caneg gout","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"722_CR42","doi-asserted-by":"publisher","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","volume":"4","author":"RD Goldfien","year":"2014","unstructured":"\u2022\u2022 Goldfien RD, Ng MS, Yip G, Hwe A, Jacobson A, Pressman A, et al. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open. 2014;4(1):e003627. \n                      https:\/\/doi.org\/10.1136\/bmjopen-2013-003627\n                      \n                    . Describes pharmacist management of gout","journal-title":"BMJ Open"},{"issue":"3","key":"722_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/tpp\/15-234.","volume":"20","author":"R Goldfien","year":"2016","unstructured":"\u2022\u2022 Goldfien R, Pressman A, Jacobson A, Ng M, Avins A. A pharmacist-staffed virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Permanente J. 2016;20(3):18\u201323. \n                      https:\/\/doi.org\/10.7812\/tpp\/15-234.\n                      \n                    . RCT of remote monitoring and treatment of gout by pharmacist","journal-title":"Permanente J"},{"key":"722_CR44","unstructured":"\u2022\u2022 Mikuls, TR CT, Rashid N, Levy GD, Kerimian A, Low K, Coburn B, Redden DT, Bridges SL Jr., Saag KG, Curtis JR. A pragmatic cluster-randomized controlled trial of an automated, pharmacy-based intervention to optimize allopurinol therapy in gout [abstract]. Arthritis Rheumatol 2015;67(Suppl 10). Ongoing cluster RCT of gout management"},{"issue":"5","key":"722_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.semarthrit.2016.10.006","volume":"46","author":"TR Fields","year":"2017","unstructured":"\u2022\u2022 Fields TR, Rifaat A, Yee AMF, Ashany D, Kim K, Tobin M, et al. Pilot study of a multidisciplinary gout patient education and monitoring program. Semin Arthritis Rheum. 2017;46(5):601\u20138. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.006\n                      \n                    . Patient education improves uptake of ULT","journal-title":"Semin Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0722-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:08:04Z","timestamp":1552003684000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0722-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"8 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Abhishek has received departmental research grants from AstraZeneca and Oxford Immunotech and has received speaker fees from Menarini pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"14"}}